Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409552 | 1.00 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1666565 | 1.00 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7354978 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7360612 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7354973 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL22370881 | 0.93 | CA12 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL20973808 | 0.93 | CA12 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL19582680 | 0.93 | CA12 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| Alcohol SCHEMBL7359179 | 0.90 | CA12 (0.46) | CA12CA1CA2CA9ALDH1A1 | |
| Butane SCHEMBL28217400 | 0.90 | CA12 (0.46) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526771-B1 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-11-30 | — | — | EP | claimed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | claimed |
| CN-102656179-A | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA CO LTD | 2012-09-05 | — | — | CN | claimed |
| EP-2470536-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2012-07-04 | — | — | EP | claimed |
| WO-2011023693-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-03-03 | — | — | WO | claimed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | claimed |
| EP-4739683-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3523280-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A BTK INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| CN-121555590-A | Method for biosynthesis of 5-hydroxy piperidine formic acid by using L-lysine | 南京工业大学 | 2026-02-24 | — | — | CN | disclosed |
| CN-121555590-A | Method for biosynthesis of 5-hydroxy piperidine formic acid by using L-lysine | 南京工业大学 | 2026-02-24 | — | — | CN | disclosed |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-0928793-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| US-5922703-A | USEFUL FOR TREATING CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0720617-B1 | NOVEL URETHANE-CONTAINING AMINOSTEROID COMPOUNDS | PROCTER & GAMBLE (US) | 1998-12-30 | — | — | EP | disclosed |
| CN-1135221-A | Urethane-containing aminosteroid compounds | PROCTER & GAMBLE (US) | 1996-11-06 | — | — | CN | disclosed |
| EP-0720617-A1 | NOVEL URETHANE-CONTAINING AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008559-A1 | NOVEL URETHANE-CONTAINING AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-30 | — | — | WO | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | CA12 4850/4885CA1 4807/4885CA2 3401/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | CA12 2672/4885CA1 4669/4885CA2 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.